| Literature DB >> 26597251 |
Joshua Kim1, Kim Garbarino2, Lonni Schultz3, Kenneth Levin4, Benjamin Movsas5, M Salim Siddiqui6, Indrin J Chetty7, Carri Glide-Hurst8.
Abstract
BACKGROUND: Magnetic resonance imaging (MRI) has been incorporated as an adjunct to CT to take advantage of its excellent soft tissue contrast for contouring. MR-only treatment planning approaches have been developed to avoid errors introduced during the MR-CT registration process. The purpose of this study is to evaluate calculated dose distributions after incorporating a novel synthetic CT (synCT) derived from magnetic resonance simulation images into prostate cancer treatment planning and to compare dose distributions calculated using three previously published MR-only treatment planning methodologies.Entities:
Mesh:
Year: 2015 PMID: 26597251 PMCID: PMC4657299 DOI: 10.1186/s13014-015-0549-7
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
MR sequence parameters
| Acquisition | Reconstruction | ||||||
|---|---|---|---|---|---|---|---|
| TR (ms) | TE (ms) | α (°) | FOV (mm3) | Voxel size (mm3) | Grid size | Voxel size (mm3) | |
| T1 Fast field echo | ~17 | 6.9 | 25 | 300x400x250 | 1.50x1.50x2.5 | 640x640x250 or 576x576x250 | 0.65x0.65x2.5 |
| T2 Turbo Spin Echo | ~5500 | 80 | 90 | 300x400x250 | 1.00x1.14x2.5 | 640x640x250 or 576x576x250 | 0.65x0.65x2.5 |
| bTFE | 5.4 | 2.7 | 75 | 300x400x250 | 1.50x1.50x2.5 | 672x672x250 or 432x432x250 | 0.65x0.65x2.5 |
Fig. 1CT and MR-derived CT surrogate images. (Top) Patient CT and T2-weighted MR images. (Bottom) MR-derived CT surrogates used for study: synthetic CT (synCT), T2 with water bulk density assignment (MRW), T2 with bulk density assignments of water and bone (MRW+B)
Average and standard deviation results for select target and OAR DVH metrics with 95 % confidence intervals in parentheses
| CT-SIM | MRW | MRW+B491 | MRW+B300 | synCT | |
|---|---|---|---|---|---|
| PTV | |||||
| D95 (Gy) | 74.9 ± 3.5 (72.9, 76.8) | 75.2 ± 3.9 (73.2, 77.2) | 73.5 ± 3.7 (71.5, 75.6) | 74.2 ± 3.8 (72.1, 76.3) | 75.1 ± 3.7 (73.2, 77.0) |
| D99 (Gy) | 73.1 ± 3.8 (71.0, 75.2) | 73.5 ± 4.1 (71.4, 75.6) | 71.8 ± 4.2 (69.4, 74.1) | 72.5 ± 4.2 (70.1, 74.8) | 73.3 ± 3.8 (71.2, 75.4) |
| Mean Dose (Gy) | 76.8 ± 3.4 (74.9, 78.7) | 77.1 ± 3.8 (75.2, 79.1) | 75.5 ± 3.6 (73.6, 77.5) | 76.2 ± 3.7 (74.2, 78.3) | 77.2 ± 3.6 (75.2, 79.2) |
| Bladder | |||||
| D15 (Gy) | 65.0 ± 10.4 (59.3, 70.8) | 64.9 ± 10.2 (59.3, 70.6) | 63.5 ± 10.6 (57.6, 69.4) | 64.0 ± 10.8 (58.0, 70.0) | 65.0 ± 10.6 (59.1, 70.9) |
| D25 (Gy) | 51.1 ± 10.5 (45.2, 56.9) | 50.8 ± 10.4 (45.0, 56.5) | 50.0 ± 10.7 (44.0, 55.8) | 50.2 ± 10.9 (44.1, 56.2) | 51.0 ± 10.5 (45.1, 56.8) |
| D35 (Gy) | 39.1 ± 10.9 (33.1, 45.2) | 38.8 ± 10.8 (32.9, 44.8) | 38.4 ± 10.8 (32.5, 44.4) | 38.6 ± 10.9 (32.5, 44.6) | 39.0 ± 10.9 (33.0, 45.1) |
| Rectum | |||||
| D15 (Gy) | 64.0 ± 6.0 (60.6, 67.3) | 64.2 ± 6.3 (61.0, 67.4) | 63.1 ± 6.1 (60.0, 66.1) | 63.6 ± 6.2 (60.4, 66.7) | 64.3 ± 6.3 (61.0, 68.0) |
| D25 (Gy) | 55.4 ± 6.9 (51.6, 59.2) | 55.5 ± 7.0 (51.9, 59.0) | 54.7 ± 6.8 (51.3, 58.2) | 55.1 ± 6.9 (51.6, 58.6) | 55.8 ± 6.8 (52.0, 59.8) |
| D35 (Gy) | 48.8 ± 7.4 (44.7, 52.9) | 48.9 ± 7.4 (45.2, 52.6) | 48.3 ± 7.3 (44.6, 52.0) | 48.6 ± 7.3 (44.9, 52.3) | 49.2 ± 7.5 (45.4, 53.0) |
| Penile Bulb | |||||
| D90 (Gy) | 13.9 ± 16.9 (4.2, 23.6) | 14.9 ± 17.0 (4.9, 24.5) | 14.6 ± 16.8 (5.1, 24.7) | 14.7 ± 16.9 (5.1, 24.8) | 14.8 ± 17.2 (4.7, 24.8) |
Fig. 2Percent difference in D95 to PTV. Percent difference in D95 to PTV between CT-based dose calculations and dose calculations derived from each CT surrogate for each patient
Fig. 3Patient dosimetric results. a Average and b worst case patient DVHs. Good agreement is observed for all treatment plans. SynCT provided closest agreement to CT-SIM results for PTV and bladder, while no significant differences were observed for rectum and penile bulb
Patient gamma analysis results for both 2 %/2 mm and 1 %/1 mm dose difference/distance to agreement
| MRW | MRW+B491 | MRW+B300 | synCT | |||||
|---|---|---|---|---|---|---|---|---|
| 2 %/2 mm | 1 %/1 mm | 2 %/2 mm | 1 %/1 mm | 2 %/2 mm | 1 %/1 mm | 2 %/2 mm | 1 %/1 mm | |
| Patient 1 | 1.00 | 0.96 | 1.00 | 0.95 | 1.00 | 0.99 | 1.00 | 0.98 |
| Patient 2 | 1.00 | 0.96 | 1.00 | 0.97 | 1.00 | 1.00 | 1.00 | 1.00 |
| Patient 3 | 0.97 | 0.90 | 1.00 | 0.99 | 1.00 | 0.98 | 1.00 | 0.99 |
| Patient 4 | 1.00 | 0.98 | 0.97 | 0.91 | 1.00 | 0.98 | 1.00 | 0.97 |
| Patient 5 | 1.00 | 0.99 | 0.96 | 0.88 | 1.00 | 0.93 | 1.00 | 0.99 |
| Patient 6 | 0.93 | 0.87 | 1.00 | 0.99 | 1.00 | 0.94 | 1.00 | 0.99 |
| Patient 7 | 0.96 | 0.91 | 1.00 | 0.99 | 1.00 | 0.96 | 1.00 | 0.99 |
| Patient 8 | 0.99 | 0.94 | 0.93 | 0.82 | 0.98 | 0.88 | 0.99 | 0.95 |
| Patient 9 | 1.00 | 0.98 | 0.96 | 0.91 | 0.99 | 0.94 | 1.00 | 0.99 |
| Patient 10 | 1.00 | 0.99 | 0.99 | 0.93 | 1.00 | 0.96 | 1.00 | 1.00 |
| Patient 11 | 1.00 | 0.82 | 0.96 | 0.64 | 0.99 | 0.72 | 1.00 | 0.90 |
| Patient 12 | 1.00 | 0.99 | 0.99 | 0.90 | 1.00 | 0.97 | 0.99 | 0.90 |
| Patient 13 | 1.00 | 0.97 | 1.00 | 0.92 | 1.00 | 1.00 | 1.00 | 0.94 |
| Patient 14 | 1.00 | 0.97 | 0.94 | 0.86 | 0.98 | 0.92 | 1.00 | 1.00 |
| Patient 15 | 1.00 | 0.98 | 0.98 | 0.90 | 1.00 | 0.94 | 1.00 | 0.99 |
| Mean | 0.99 | 0.95 | 0.98 | 0.90 | 1.00 | 0.94 | 1.00 | 0.97 |
| Min | 0.93 | 0.82 | 0.93 | 0.64 | 0.98 | 0.72 | 0.99 | 0.90 |
| Max | 1.00 | 0.99 | 1.00 | 0.99 | 1.00 | 1.00 | 1.00 | 1.00 |
Fig. 4Patient gamma analysis results. Dose plans at isocenter derived from a CT-SIM and b synCT and resulting c gamma distribution (pass rate: 99.95 %) evaluated at 1 %/1 mm for a typical patient (Patient 14) treated to 78 Gy. d Line profile through a compares dose differences between CT-SIM and CT surrogates
Fig. 5Case study. Visible increase in rectal air volume during MR simulation relative to CT simulation for Patient 11 seen when comparing a T2-weighted MR image, b CT-SIM, and c synCT. Resulting differences in dose distributions at isocenter from d CT-SIM were seen in e dose distributions from synCT but not from methods assigning bulk electron density values to f water, h water + bone (491 HU), and i water + bone (300 HU). Increased dose for synCT can be seen in g vertical line profiles taken through dose planes at isocenter